Obesity, a personal struggle and a public health crisis, has found a promising solution in a new class of drugs. Glucagon-like peptide-1 (GLP-1) agonists, originally developed for diabetes, have emerged as a groundbreaking treatment for obesity, earning the title of Science’s Breakthrough of the Year. Jennifer Couzin-Frankel’s insightful report reveals the transformative potential of these therapies in treating not only obesity but also its associated health issues.

Historically, obesity treatments have been fraught with risks and limited efficacy. From the amphetamine-laden “rainbow diet pills” of the 1940s to the fen-phen debacle of the 1990s, the journey to find safe and effective weight loss drugs has been challenging. However, GLP-1 drugs, mimicking a gut hormone, have marked a significant shift in this narrative.

The pharmaceutical journey of GLP-1 began in the early 1980s with diabetes research. By the 1990s, it was discovered that GLP-1 could reduce food intake, leading to its exploration as a weight-loss treatment. The first GLP-1 drug, exenatide (Byetta), was approved in 2005, followed by liraglutide (Victoza) and later, semaglutide (Ozempic for diabetes and Wegovy for obesity).

Semaglutide’s approval in 2021 for obesity treatment sparked widespread interest. Clinical trials have shown that it can lead to a significant 15% body weight loss over 16 months. Furthermore, it reduces the incessant desire to eat, commonly referred to as “food noise.”

The impact of GLP-1 drugs extends beyond weight loss. In 2023, studies revealed that semaglutide could improve heart function in people with obesity and heart failure.

It also reduces the risk of heart attacks and strokes in individuals with excess weight and cardiovascular disease. This data underscores the far-reaching health benefits of GLP-1 drugs, beyond mere weight reduction.

Nevertheless, the excitement surrounding these drugs is tempered with caution. Side effects like nausea and gastrointestinal problems are common, and there are concerns about their long-term use and affordability. Priced at over $1000 per month, the cost poses a significant barrier, particularly considering the likelihood of lifelong treatment.

Looking ahead, the horizon of GLP-1 drugs is expanding. Trials are exploring their potential in treating drug addiction, Alzheimer’s, and Parkinson’s diseases, thanks to their influence on brain receptors related to desire.

The introduction of GLP-1 agonists is reshaping the medical and societal perception of obesity. No longer viewed simply as a failure of willpower, obesity is increasingly understood as a chronic illness rooted in biology. This shift in perspective is crucial in reducing stigma and improving treatment approaches.

The future of GLP-1 drugs looks promising but comes with a host of questions and challenges. Issues of cost, long-term safety, and the need for ongoing treatment are among the concerns that need addressing. Nonetheless, the breakthrough of GLP-1 drugs represents a significant stride in obesity treatment, offering hope for millions struggling with excess weight and its health implications.

View source version on https://www.science.org/content/article/breakthrough-of-the-year-2023